polycystic liver disease
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • 18 yrs-of age • Multiple livercysts > 20 in PCLD- or ADPKD-patients • Cooperating patient • Is willing and able to comply with the study drug regimen and all other study requirements. • Willingness to give written informed consent
Exclusion criteria
Exclusion criteria: • Use of oral anticonceptives or estrogen suppletion • Females who are pregnant or breast-feeding • History or other evidence of chronic pulmonary disease associated with functional limitation • History of severe cardiac disease (eg, NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases). In addition, patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled. • History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study • Symptomatic gallstones (lanreotide decreases gall bladder volume) • Renal failure requiring hemodialysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of total liver volume as determined by multidetector CT scan (MDCT). | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of liver volume and individual cyst volume on MDCT. Symptom evaluation by validated questionnaire | — |
Countries
Netherlands
Outcome results
None listed